anastrozole and fulvestrant in hormone receptor-positive breast cancer
Published 11 years ago • 3.6K plays • Length 5:50Download video MP4
Download video MP3
Similar videos
-
5:50
anastrazole and fulvestrant in hormone receptor-positive breast cancer
-
3:38
treating early breast cancer
-
7:46
san antonio roundtable, part 1: fulvestrant dose and tamoxifen duration
-
3:59
adjuvant aromatase inhibitors
-
0:27
how to cope with tamoxifen and letrozole
-
6:25
combination of anastrozole and fulvestrant in metastatic breast cancer
-
6:55
fulvestrant versus anastrozole in patients with advanced breast cancer
-
6:23
alternate: fulvestrant and/or anastrozole in er her2- postmenopausal breast cancer
-
1:18
the significance of fulvestrant for hormone receptor-positive advanced breast cancer
-
0:20
cutting the risk of breast cancer
-
5:03
role of fulvestrant monotherapy in hr mbc
-
6:37
the estrogen-receptor antagonist fulvestrant in breast cancer
-
0:31
which metastatic breast cancer often don't respond to aromatase inhibitors?
-
10:55
san antonio roundtable, part 4: everolimus in clinical practice, a new cdk inhibitor
-
5:28
comment: fulvestrant improves survival over anastrozole for patients with advanced breast cancer
-
1:00
what are aromatase inhibitors?
-
2:30
germain, adelson: fulvestrant for hr breast cancer
-
1:05
dr. verma on palbociclib plus fulvestrant for hr /her2- breast cancer
-
1:13
what is hormone receptor positive (er /her2-) advanced breast cancer?